Corbus Pharmaceuticals updates investor presentation on CRB-701 and CRB-913 programs
On October 15, 2026, Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation that management uses to describe its business. The presentation covers early clinical data for its CRB-701 cancer drug and CRB-913 obesity drug, but it contains no new financial results or guidance, and the filing is furnished rather than filed.
Key points
- Cash, cash equivalents and investments were $118 million as of June 30, 2026, per the presentation.
- CRB-701 first patient was dosed in the registrational TEMPO-1 study in September 2026; topline data in first-line OPSCC expected in Q1 2027.
- CRB-913 Phase 1b CANYON-1 study (254 patients) showed 5% placebo-adjusted weight loss at 12 weeks on the 60mg dose; Phase 2 expected to start in 1H 2027.
- About 18.7 million common shares were outstanding (about 22.4 million fully diluted).
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.